AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19302649 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 60
Study 19302649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60
Study 17394073 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-cm upper endoscope
Number of subjects: 81
Study 17394073 — intervention group
Group type: COMPARATOR
Intervention: 60-cm sigmoidoscope
Number of subjects: 81
Study 15446534 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction
Number of subjects: 102
Study 15446534 — intervention group
Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 102
Study 15446534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (closed and open reduction)
Number of subjects: 102
Study 11441324 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lozenges (four to six lozenges/day for 10 days)
Number of subjects: 48
Study 11441324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9671436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) applied for five days
Number of subjects: 14
Study 9671436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8% NCT applied for five days
Number of subjects: 14
Study 9671436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% and 3% NCT regimen applied for nine days in rabbits
Number of subjects: 14
Study 7675378 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 pessary
Number of subjects: 155
Study 7675378 — intervention group
Group type: COMPARATOR
Intervention: Placebo pessary
Number of subjects: 155
Study 2291748 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized garlic-powder tablets (800 mg daily for 16 weeks)
Number of subjects: 261
Study 2291748 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (same number as garlic tablets for 16 weeks)
Number of subjects: 261
Study 6157050 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase for 24 hours
Number of subjects: 0
Study 6157050 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 30148436 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 30148436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28865799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg PO
Number of subjects: 30
Study 28865799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 400 mg PO
Number of subjects: 30
Study 28865799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 600 mg PO
Number of subjects: 30
Study 28865799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (all doses)
Number of subjects: 30
Study 28865799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26362172 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine
Number of subjects: 31989
Study 23702263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted participants (intervention group)
Number of subjects: 80
Study 23702263 — intervention group
Group type: COMPARATOR
Intervention: Non-fasted participants (control group)
Number of subjects: 80
Study 23702263 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating manipulation (fasting before testing)
Number of subjects: 80
Study 20979461 — intervention group
Group type: EXPERIMENTAL
Intervention: E2+DRSP (17β‐estradiol 1 mg/day plus drospirenone 2 mg/day)
Number of subjects: 100
Study 20979461 — intervention group
Group type: COMPARATOR
Intervention: Calcium (control)
Number of subjects: 100
Study 19489490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group A
Number of subjects: 279
Study 19489490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group B
Number of subjects: 279
Study 19489490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group C
Number of subjects: 279
Study 19489490 — intervention group
Group type: COMPARATOR
Intervention: Control group (Prednisone only)
Number of subjects: 279
Study 17203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave (CW) EMF exposure (0.25 W)
Number of subjects: 36
Study 17203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed modulated (PM) EMF exposure (mean 0.25 W)
Number of subjects: 36
Study 17203481 — intervention group
Group type: COMPARATOR
Intervention: Sham EMF exposure (control group of 16 subjects)
Number of subjects: 36
Study 15019795 — intervention group
Group type: COMPARATOR
Intervention: Healthy normally cycling women (Control)
Number of subjects: 27
Study 15019795 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with major depression (Intervention)
Number of subjects: 27
Study 15019795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (sub-analysis)
Number of subjects: 27
Study 11705426 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 234
Study 9270575 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 75
Study 9270575 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 75
Study 9270575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8001289 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based enzyme immunoassay (EIA) for urinary 18-hydroxycortisol
Number of subjects: 27
Study 8001289 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-adrenalectomy urinary 18-hydroxycortisol level
Number of subjects: 27
Study 3078281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trifluoperazine (TFP) 7 mg
Number of subjects: 14
Study 3078281 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled trifluoperazine (TFP) 10 mg/ml, nebulized for 5 min
Number of subjects: 14
Study 3078281 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for inhaled TFP)
Number of subjects: 14
Study 30714059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bristleless toothbrush
Number of subjects: 23
Study 30714059 — intervention group
Group type: COMPARATOR
Intervention: Soft nylon-bristled toothbrush
Number of subjects: 23
Study 28262330 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol prophylaxis
Number of subjects: 0
Study 28262330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen prophylaxis
Number of subjects: 0
Study 28262330 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 0
Study 26321734 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training application
Number of subjects: 0
Study 26321734 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 22970725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment (LVR)
Number of subjects: 29
Study 22970725 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study 19954996 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle flap group (intercostal muscle flap + intracostal suture)
Number of subjects: 144
Study 19954996 — intervention group
Group type: COMPARATOR
Intervention: Control group (intracostal suture only)
Number of subjects: 144
Study 19142041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham kinesiology treatment (administered weekly for 5 weeks)
Number of subjects: 20
Study 19142041 — intervention group
Group type: EXPERIMENTAL
Intervention: Real kinesiology treatment (4 sessions)
Number of subjects: 20
Study 19142041 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesiology treatment (4 sessions)
Number of subjects: 20
Study 16324923 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide (10 mg)
Number of subjects: 16
Study 16324923 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride (4 mg)
Number of subjects: 16
Study 16324923 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 14689407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cardiac stress testing
Number of subjects: 99
Study 14689407 — intervention group
Group type: COMPARATOR
Intervention: No stress testing (Control)
Number of subjects: 99
Study 11081528 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (n=63)
Number of subjects: 124
Study 11081528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 124
Study 8885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to food allergens (egg white, fish, wheat, peanut, soy, milk)
Number of subjects: 1812
Study 8885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of food intolerance
Number of subjects: 1812
Study 8885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to food allergens
Number of subjects: 1812
Study 8885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to food allergens
Number of subjects: 1812
Study 8885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic subjects, subjects with current asthma, and subjects with bronchial hyperresponsiveness
Number of subjects: 1812
Study 1525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 90% USRDA of Mg
Number of subjects: 49
Study 1525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 180% USRDA of Mg
Number of subjects: 49
Study 1525984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 4091884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine treatment (500 mg/day) for 30 days
Number of subjects: 27
Study 4091884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30682576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindset that non-life-threatening symptoms can signal desensitization
Number of subjects: 50
Study 30682576 — intervention group
Group type: COMPARATOR
Intervention: Mindset that non-life-threatening symptoms are unfortunate side effects of treatment
Number of subjects: 50
Study 30307416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track rehabilitation (FTR)
Number of subjects: 86
Study 30307416 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 86
Study 26832780 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control)
Number of subjects: 90
Study 26832780 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex® fluid
Number of subjects: 90
Study 26832780 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector S
Number of subjects: 90
Study 25270426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 168
Study 25270426 — intervention group
Group type: COMPARATOR
Intervention: U.S. Food and Drug Administration recommended pharmacologic treatments (RPT)
Number of subjects: 168
Study 25270426 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (TAU)
Number of subjects: 168
Study 22828681 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Number of subjects: 120
Study 22828681 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural injections of 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 120
Study 22828681 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for both groups
Number of subjects: 120
Study 22828681 — intervention group
Group type: EXPERIMENTAL
Intervention: Average relief per procedure
Number of subjects: 120
Study 20663275 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (IMT)
Number of subjects: 80
Study 20663275 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing exercises
Number of subjects: 80
Study 20663275 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 80
Study 20663275 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 80
Study 17440642 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum immune modulatory therapy
Number of subjects: 2400
Study 17440642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 15116072 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high intake of zinc (811 micromol/day; 53 mg/day)
Number of subjects: 28
Study 15116072 — intervention group
Group type: COMPARATOR
Intervention: Low dietary zinc (45.9 micromol/day; 3 mg/day)
Number of subjects: 28
Study 15116072 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary zinc (811 micromol/day; 53 mg/day)
Number of subjects: 28
Study 12008939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 12008939 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 12008939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 12008939 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic prophylaxis (stopped at hospital discharge)
Number of subjects: 0
Study 12008939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis extended to 4 weeks
Number of subjects: 0
Study 12008939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis extended to 6 weeks
Number of subjects: 0
Study 9823995 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 319
Study 9823995 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 319
Study 8088198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs (A)
Number of subjects: 16
Study 8088198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-acupuncture (B)
Number of subjects: 16
Study 8088198 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (C)
Number of subjects: 16
Study 8088198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs (A) and Ear-acupuncture (B)
Number of subjects: 16
Study 8088198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2733993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral colchicine (1.2 mg/day)
Number of subjects: 0
Study 2733993 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (250 mg/day orally)
Number of subjects: 0
Study 31660788 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA) alone
Number of subjects: 90
Study 31660788 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA) with tumescent anaesthesia (G + T)
Number of subjects: 90
Study 28168567 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended targeted retinal photocoagulation (ETRP)
Number of subjects: 270
Study 28168567 — intervention group
Group type: COMPARATOR
Intervention: Conventional pan-retinal photocoagulation (CPRP)
Number of subjects: 270
Study 27620647 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric meal with erythritol
Number of subjects: 20
Study 27620647 — intervention group
Group type: COMPARATOR
Intervention: Control sucrose meal
Number of subjects: 20
Study 27620647 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic meal with erythritol
Number of subjects: 20
Study 24021298 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill gait training (PWSTT) with unloading of 20% of body weight
Number of subjects: 60
Study 24021298 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60
Study 24021298 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable dosage of dopaminomimetic drugs only)
Number of subjects: 60
Study 24021298 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill gait training (PWSTT)
Number of subjects: 60
Study 23750500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (0.7 litres/day) for 60 days
Number of subjects: 56
Study 23750500 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 56
Study 21294931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) 50,000 IU (15 mg) at birth
Number of subjects: 4183
Study 21294931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4183
Study 19041130 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 3526
Study 19041130 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 3526
Study 16141379 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline (one puff per nostril)
Number of subjects: 20
Study 16141379 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 14675268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once a morning
Number of subjects: 85
Study 14675268 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once a morning
Number of subjects: 85
Study 14675268 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once a morning
Number of subjects: 85
Study 10721243 — intervention group
Group type: EXPERIMENTAL
Intervention: PG universal retraction springs
Number of subjects: 36
Study 10721243 — intervention group
Group type: COMPARATOR
Intervention: Closed coil spring system
Number of subjects: 36
Study 9187529 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl)
Number of subjects: 0
Study 9187529 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 1435800 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (9 million units/m2 body surface area three times a week for four months)
Number of subjects: 24
Study 1435800 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 1435800 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 24
Study 3157709 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% erythromycin ointment
Number of subjects: 208
Study 3157709 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 208
Study 31554419 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL16 admission levels
Number of subjects: 5142
Study 31554419 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL16 admission levels (adjusted)
Number of subjects: 5142
Study 31554419 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL16 measured at 1 month
Number of subjects: 5142
Study 31554419 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CXCL16 from admission to 1 month
Number of subjects: 5142
Study 29980419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral skin incision
Number of subjects: 118
Study 29980419 — intervention group
Group type: COMPARATOR
Intervention: Anteromedial skin incision
Number of subjects: 118
Study 27106640 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic group
Number of subjects: 112
Study 27106640 — intervention group
Group type: COMPARATOR
Intervention: Extended antibiotic group
Number of subjects: 112
Study 24806263 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg/day)
Number of subjects: 16
Study 24806263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23187987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 32
Study 23187987 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 32
Study 19643937 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy efficiency upgrading in homes of COPD patients
Number of subjects: 178
Study 19643937 — intervention group
Group type: COMPARATOR
Intervention: Independent energy efficiency action by patients
Number of subjects: 178
Study 18403946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1200 mg)
Number of subjects: 24
Study 18403946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17158440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil fatty acid esters of plant sterols (FO-PS)
Number of subjects: 21
Study 17158440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil esters of plant sterols (SU-PS)
Number of subjects: 21
Study 17158440 — intervention group
Group type: COMPARATOR
Intervention: Control (Olive Oil - OO)
Number of subjects: 21
Study 17158440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 21
Study 12715486 — intervention group
Group type: EXPERIMENTAL
Intervention: Profore (multilayer elastic compression)
Number of subjects: 89
Study 12715486 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch compression
Number of subjects: 89
Study 10634827 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin + omega-3 fatty acids at 3.36 g/d
Number of subjects: 41
Study 8939178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily for 12 weeks
Number of subjects: 32
Study 8939178 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 0.2 mg four times daily for 12 weeks
Number of subjects: 32
Study 1382927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution therapy (by rapid venesection, venous infusion of autologous plasma and 500 ml dextran 40)
Number of subjects: 92
Study 1382927 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 92
Study 1382927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution therapy
Number of subjects: 92
Study 1382927 — intervention group
Group type: COMPARATOR
Intervention: Hemodilution therapy and Standard therapy
Number of subjects: 92
Study 3887882 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically prescribed and supervised regular physical activity
Number of subjects: 0
Study 3887882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3887882 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen (frequency of attendance and intensity differed)
Number of subjects: 0
Study 3887882 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study 31272313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified ARV regimen
Number of subjects: 368
Study 31272313 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate number of ARV drug changes (up to 2 per 6 months)
Number of subjects: 368